News:

August 21, 2008
Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject(TM) at the 12th World Congress on Pain

August 12, 2008
Javelin Presents PMI-150 (Intranasal Ketamine) Data at Premier Department of Defense Scientific Meeting

August 11, 2008

Javelin Pharmaceuticals, Inc. to Present at 28th Annual Canaccord Adams Global Growth Conference in Boston

August 7, 2008
Javelin Pharmaceuticals Reports Second Quarter 2008 Financial Results

August 1, 2008
Javelin Pharmaceuticals to Announce Second Quarter 2008 Financial Results

July 31, 2008
Javelin Pharmaceuticals and Baxter Healthcare Corporation Expand Commercial Supply Relationship for Anticipated Dyloject(TM) Global Growth

June 10, 2008
Javelin Pharmaceuticals Enrolls First Patient in Pivotal Trial
for PMI-150

June 5, 2008
Javelin Pharmaceuticals' Founder and President Transitions to Executive Director

June 4, 2008
Javelin Announces New Patent Covering PMI-150 (Intranasal Ketamine)